Llwytho...
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indication. Accompanying these advances, the 2018 Nobel Prize was awarded for the discovery of im...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Hematol Oncol |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7119170/ https://ncbi.nlm.nih.gov/pubmed/32245497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00862-w |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|